Psoriasis, biologic therapy, and the pandemic of the 21st century

Psoriasis, biologic therapy, and the pandemic of the 21st century

Tiago Torres, Miguel Nogueira, Ron Vender

The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient.

2020

psoriasis, coronavirus, biologic, SARS-CoV-2, COVID-19

DOI: 10.7573/dic.2020-4-10

Drugs in Context

BioExcel Publishing Ltd

Therapeutics. Pharmacology